Immuron Limited (ASX:IMC)

Market Cap	14.72M
Revenue (ttm)	6.54M
Net Income (ttm)	-7.35M
Shares Out	233.71M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,841
Average Volume	179,028
Open	0.0640
Previous Close	0.0650
Day's Range	0.0630 - 0.0640
52-Week Range	0.0540 - 0.1100
Beta	0.96
RSI	46.73
Earnings Date	May 29, 2025

About Immuron

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive func...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 7
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IMC

Financial Performance

In 2024, Immuron's revenue was 4.90 million, an increase of 171.67% compared to the previous year's 1.80 million. Losses were -6.94 million, 83.2% more than in 2023.